Novo Nordisk Advances DKK 15 Billion Share Buyback, Lifts Treasury Stake to 0.5%
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Novo Nordisk ( (NVO) ) just unveiled an update.
On 4 February 2026, Novo Nordisk launched a 12‑month share repurchase programme of up to DKK 15 billion, structured under EU Safe Harbour rules to provide regulatory protection for its buyback activity. Under a specific sub‑programme running from 4 February to 4 May 2026, the company plans to buy back up to DKK 3.8 billion of its B shares, reinforcing capital return to shareholders and signaling confidence in its long‑term prospects.
Between 16 and 20 February 2026, Novo Nordisk repurchased an additional 1,000,000 B shares, bringing total buybacks since 4 February to 2,750,000 B shares at an average price of DKK 306.18 and a transaction value of about DKK 842 million. As of 20 February 2026, the company held 20,139,799 B shares as treasury stock, equal to 0.5% of its share capital, a move that slightly reduces free float and can support earnings per share over time while maintaining flexibility within its broader capital allocation strategy.
The most recent analyst rating on (NVO) stock is a Hold with a $45.00 price target. To see the full list of analyst forecasts on Novo Nordisk stock, see the NVO Stock Forecast page.
Spark’s Take on NVO Stock
According to Spark, TipRanks’ AI Analyst, NVO is a Neutral.
The score reflects strong underlying financial quality and attractive valuation, partially offset by a very weak technical setup (downtrend across all key moving averages) and a cautious near-term outlook from management, including guidance for declining 2026 sales and operating profit amid pricing and policy headwinds.
To see Spark’s full report on NVO stock, click here.
More about Novo Nordisk
Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark, with a core focus on defeating serious chronic diseases rooted in its diabetes heritage. The company pioneers scientific breakthroughs, works to expand access to its medicines, and employs about 68,800 people in 80 countries while marketing its products in around 170 countries, with B shares listed on Nasdaq Copenhagen and ADRs on the New York Stock Exchange.
The group’s broad global footprint and dual listings underscore its position as a key player in the biopharmaceutical sector, where its therapies and pipeline developments are closely watched by investors and healthcare systems alike.
Average Trading Volume: 21,464,309
Technical Sentiment Signal: Sell
Current Market Cap: $217.7B
For detailed information about NVO stock, go to TipRanks’ Stock Analysis page.
